Cargando…

Androgen deprivation and cognition in prostate cancer

Androgen deprivation (AD) is commonly used in neoadjuvant and adjuvant setting with prostate cancer (PC) radiotherapy. This prospective study assessed whether cognitive functioning is impaired during 12 months of AD therapy. Longitudinal testing of 25 patients treated with AD and curative radiothera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salminen, E, Portin, R, Korpela, J, Backman, H, Parvinen, L-M, Helenius, H, Nurmi, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376935/ https://www.ncbi.nlm.nih.gov/pubmed/12966411 http://dx.doi.org/10.1038/sj.bjc.6601235

Ejemplares similares

Weight Loss for Obese Prostate Cancer Patients on Androgen Deprivation Therapy
por: WILSON, REBEKAH L., et al.
Publicado: (2021)

Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy
por: Saylor, Philip J., et al.
Publicado: (2009)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Resistance Exercise Training Increases Muscle Mass and Strength in Prostate Cancer Patients on Androgen Deprivation Therapy
por: HOUBEN, LISANNE H. P., et al.
Publicado: (2023)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma
por: Sanguineti, G, et al.
Publicado: (2002)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases
por: Varenhorst, Eberhard, et al.
Publicado: (2016)

Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer
por: Gilbert, Stephen E, et al.
Publicado: (2016)

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
por: Parker, C C, et al.
Publicado: (2002)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

The clinical guiding value of a radiomics model for androgen deprivation therapy for prostate cancer
por: Yu, Na, et al.
Publicado: (2021)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer
por: Al-Shamsi, Humaid O., et al.
Publicado: (2012)

Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer
por: Salji, M, et al.
Publicado: (2014)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Androgen deprivation and SARS-CoV-2 in men with prostate cancer
por: Koskinen, M., et al.
Publicado: (2020)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review
por: Andela, Cornelie D, et al.
Publicado: (2021)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
por: Terrisse, Safae, et al.
Publicado: (2022)

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
por: Shim, Myungsun, et al.
Publicado: (2022)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy
por: Shiota, Masaki, et al.
Publicado: (2015)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
por: Bagrodia, Aditya, et al.
Publicado: (2009)

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
por: Wadosky, Kristine M., et al.
Publicado: (2016)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_arl0lpivgeo492algoi7714nr1